Cellerant Therapeutics Appoints Ramkumar Mandalam as Vice President of Pharmaceutical Operations.SAN CARLOS, Calif. -- Cellerant Therapeutics, Inc. today announced that Ramkumar Mandalam, Ph.D., has joined Cellerant Therapeutics as Vice President of Pharmaceutical Operations. Dr. Mandalam was formerly Executive Director of Product Development for Geron Corporation. "Ram is an instrumental addition to our team as he brings with him extensive experience in the production of cell-based products and the regulation and manufacture of cell products and biologics. Ram's technical and industry knowledge will be particularly valuable as we bring our lead product CLT-001, a highly purified adult blood stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. infusion, into the clinic, and move forward with the development and manufacturing of the other products in our pipeline," stated Bruce Cohen cohen or kohen (Hebrew: “priest”) Jewish priest descended from Zadok (a descendant of Aaron), priest at the First Temple of Jerusalem. The biblical priesthood was hereditary and male. , President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Cellerant. "Cellerant is a leader in cell-based therapies for complex, life-threatening diseases. The company's technology platform, based on adult blood-forming stem cells stem cells, unspecialized human or animal cells that can produce mature specialized body cells and at the same time replicate themselves. Embryonic stem cells are derived from a blastocyst (the blastula typical of placental mammals; see embryo), which is very young , represents a unique approach to therapy which moves cell therapy from personalized medicine to off-the-shelf product manufacturing," stated Dr. Mandalam. "I am excited about the prospect of advancing the company's ambitious programs and setting the standard for the development and manufacture of a wide range of cell-based drugs and services." Dr. Mandalam was previously Executive Director of Product Development at Geron Corporation, where he managed the development and manufacturing of cell based therapies for treatment of degenerative diseases and cancer. Prior to Geron, he was Director of Developmental Research at Aastrom Biosciences, where he was responsible for the research and development programs involving ex vivo ex vivo /ex vi·vo/ (eks´ ve´vo) outside the living body; denoting removal of an organ (e.g., the kidney) for reparative surgery, after which it is returned to the original site. expansion of human bone marrow stem cells and dendritic cells. Dr. Mandalam received his Ph.D. in Chemical Engineering from the University of Michigan (body, education) University of Michigan - A large cosmopolitan university in the Midwest USA. Over 50000 students are enrolled at the University of Michigan's three campuses. The students come from 50 states and over 100 foreign countries. . Dr. Mandalam is the author or co-author of several publications, patent applications, and abstracts. About Cellerant Therapeutics Cellerant Therapeutics is a commercial-stage company developing a portfolio of products and services focused on the regulation of the hematopoietic hematopoietic /he·ma·to·poi·et·ic/ (-poi-et´ik) 1. pertaining to hematopoiesis. 2. an agent that promotes hematopoiesis. hematopoietic 1. pertaining to or affecting the formation of blood cells. (blood-forming) system. Our products are based on adult hematopoietic stem and progenitor cells as both therapeutic agents and targets for drug discovery. Visit our website at http://www.cellerant.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion